跳至主要内容
临床试验/NCT00004583
NCT00004583已完成3 期

A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral Naive HIV-Infected Subjects

Abbott83 个研究点 分布在 11 个国家目标入组 660 人开始时间: 1999年3月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
660
试验地点
83

研究概览

简要总结

The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV).

Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.

详细描述

Based on the accumulated studies to date, it is expected that ABT-378/ritonavir will provide efficacy that is at least as good as (or superior to) nelfinavir when used in combination with reverse transcriptase inhibitors.

Patients are equally randomized to one of two treatment arms. In one arm, approximately 330 patients receive ABT-378/ritonavir plus nelfinavir placebo. In the other arm, approximately 330 patients receive nelfinavir plus ABT-378/ritonavir placebo. In both arms, these protease inhibitors are blinded to the investigator, patient, and sponsor. Both arms receive open-label stavudine and lamivudine. Vital sign measurements, physical examinations, ECGs, routine clinical laboratory evaluations, and determinations of antiviral and immunologic activity are performed at intervals throughout the study.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
Double

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •You may be eligible for this trial if you:
  • •Are HIV positive.
  • •Have a viral load (level of HIV in your blood) of more than 400 copies/ml.
  • •Are age 12 or older.
  • •Agree to practice abstinence or use effective methods of birth control during the study.

排除标准

  • •You will not be eligible for this trial if you:
  • •Have taken anti-HIV drugs for more than 14 days in the past, or if you have ever taken d4T or 3TC.
  • •Are seriously ill or have an AIDS-related infection.
  • •Are pregnant or breast-feeding.
  • •Are taking certain medications.

研究者

发起方
Abbott
申办方类型
Industry

研究点 (83)

Loading locations...

相似试验